

Index

A

- ACC (adrenocortical carcinoma), 38–41, 44
- ACT. *See* Adoptive cell therapy (ACT) for solid tumors
- Actinomycin D, 230
- Acute lymphoblastic leukemia (ALL)
 - in adolescent and young adult (AYA) population, 229–230
 - B-ALL (*see* B-cell acute lymphoblastic leukemia)
 - genetic predisposition syndrome (GPS), 7
 - RAG1/2, 3
 - Ras pathway alterations, 111
 - survival improvement percentage, history of, 228
 - T-ALL (*see* T-cell acute lymphoblastic leukemia)
- Acute lymphoblastic leukemia (ALL) treatment
 - asparaginase, 241
 - chemotherapy, 226–231
 - immunotherapies, 187–201
 - overview, 226–233
- Acute myeloid leukemia (AML)
 - bone marrow analysis, 11
 - IDH mutations, 243–244, 277, 281
 - modeling, 73–74
 - PLM and, 217
 - RAG1/2, 3
 - Ras pathway alterations, 110–111
- Acute myeloid leukemia (AML) treatment
 - all-*trans* retinoic acid and arsenic trioxide (ATRA), 217, 285
 - asparaginase, 241
 - duration of therapy, 233
 - enasidenib, 277
 - histone acetyltransferase (HAT) inhibitors, 281–282
 - ivosidenib, 277, 281
- Acute promyelocytic leukemia (APL)
 - biology of oncogenesis, 210
 - broadening lessons from APL model to other AMLs, 216–217
 - cell differentiation, 213
 - cell of origin, 212
 - duration of therapy, 233
 - introduction, 209–210
 - PML/RARA as master driver of classic, 210–211
 - review, 209–217
 - treatment, 209–210, 212–216
- ADC (antibody-drug conjugate), CD22-targeted, 190
- Adoptive cell therapy (ACT) for solid tumors
 - antigen escape, 257
 - CAR-T, 261–262
 - clinical use, approach to ACT in, 262–266
 - considerations for targeting, 256–260
 - future directions, 266
 - generation of ACT products, 260–262
 - immunosuppressive tumor microenvironment, overcoming, 257–260
 - introduction, 255–256
 - location and homing, 260
 - MHC loss/down-regulation, 257
 - review, 255–266
 - summary of ACT products, 263
 - summary of different approaches, 261
 - target identification, 256–257
 - TCR-specific products, 262
 - tumor-infiltrating lymphocytes (TILs), 260–261
- Adrenergic (ADRN) neuroblastoma cells, 173, 175–180
- Adrenocortical carcinoma (ACC), 38–41, 44
- Adult-onset cancer and childhood cancer compared
 - driver mutations, 56
 - drug development, 293–310
 - hereditary cancers, 36–37
 - immune context, 299, 304–305
 - models, 83
 - molecular landscape, 298–299
- AID, 1, 3–4
- ALL. *See* Acute lymphoblastic leukemia
- All-*trans* retinoic acid (ATRA), 157, 209–210, 213–217, 285–286
- Alveolar rhabdomyosarcoma (ARMS), 74, 84–85, 88–89
- Amino acid homeostasis, as therapeutic vulnerability, 240–242
- Aminopterin, 226–228, 239–240, 293
- AML. *See* Acute myeloid leukemia
- Androgen receptor, expression in osteosarcoma, 156
- Animal models
 - blood cancers, 73
 - brain tumors, 71–73
 - genetically engineered mouse models (GEMMs), 69–73, 75, 114
 - osteosarcoma, 152
 - overview, 68–69
 - rhabdomyosarcoma (RMS) models, 88–92
- Antibody-drug conjugate (ADC), CD22-targeted, 190
- Antifolates, 239–240
- Antigen escape, 257
- Antigen-presenting cells (APCs), 193, 195, 262
- Antimetabolite resistance, 240
- Antimetabolites, 239–240
- Anti-PD-1/PD-L1 treatment, 299
- Antitumor immunity, improving, 244–245
- APCs (antigen-presenting cells), 193, 195, 262

Index

- APL. *See* Acute promyelocytic leukemia
ARAF mutations, 111, 116
Arginine, 245
ARMS (alveolar rhabdomyosarcoma), 74, 84–85, 88–89
Arsenic trioxide (ATO), 209–210, 213–217, 285–286
ASCL1, 178–179
Asparaginase, 240–242
Asparaginase resistance, 241–242
ATRA (all-*trans* retinoic acid), 157, 209–210, 213–217, 285–286
Azacitidine, 157, 275–276, 281, 285
- B**
- B-cell acute lymphoblastic leukemia (B-ALL)
 blinatumomab treatment, 232
 CAR-T, 261
 driver mutations, 59
 history of treatment approaches, 229
 immunotherapies, 188–191
 Ras pathway alterations, 111
 ultraviolet light signatures in, 57
Best Pharmaceuticals for Children Act (BPCA), 295–296
BET inhibitors, 282
Bevacizumab, 198–199
Biologics Licensing Application (BLA), 295–296
Biologics Price Competition and Innovation Act (BPCIA), 295
- Biomarkers
 DNA methylation as, 44
 ICI response, 304
 immunotherapy response, 304–305
Bispecific antibodies (BsAbs)
 CD19, 188–189
 GD2, 193
BLA (Biologics Licensing Application), 295–296
Blinatumomab, 188–190, 193, 232
Bliss Independence analysis, 113
Blood cancers. *See also specific cancers*
 animal models, 73
 cell-based models, 73–74
Bloom syndrome, 155
Bone development
 osteoclasts, role of, 151
 signaling pathways, 150–151
 transcription factors, 150–151
Bone marrow analysis
 for disease surveillance, 27
 genetic predisposition syndrome (GPS), 11–12
Bone morphogenetic protein (BMP), 134, 139–140
Bone remodeling, 151–152, 154–155, 159
BPCA (Best Pharmaceuticals for Children Act), 295–296
BPCIA (Biologics Price Competition and Innovation Act), 295
BRAF mutations, 107, 110, 112–116, 298
Brain tumors
 cell-based models, 69–71
 Ras pathway alterations, 112–113
Breast cancer, and Li–Fraumeni syndrome (LFS), 38, 40–41, 44
Bromodomain inhibitors, 282
BsAbs (bispecific antibodies), 188–189, 193
- C**
- Cabozantinib, 157
Cancer-associated fibroblasts (CAFs), 126, 129–131, 135–136, 138–139, 158–159, 259
Cancer predisposition syndromes, 35–37, 46–47
Cancer stem cells (CSCs)
 developmental signaling, 129, 135, 137–138, 140–141
 immunotherapies targeting, 129, 199
 in tumor microenvironment (TME), 129
Cancer surveillance
 in genetic predisposition syndrome (GPS), 26–27
 Li–Fraumeni syndrome (LFS), 38–46
 machine learning for, 45–46
 noninvasive screening and monitoring, 44–45
 personalized, 40–46
Cancer susceptibility genes (CSGs), 37, 44
CAR-NK cell products, 262
CAR T-cell therapy
 acute lymphoblastic leukemia (ALL), 232
 CD19, 189–190
 CD22, 190–191
 dual CD19 and CD22 targeting CAR T-cell therapy, 191
 GD2, 192–193, 199
 generation of products, 261–262
 immunometabolic pathways, targeting of, 245
 immunotherapies, 187–193, 196, 199
Cascade testing, 27
CCA (conventional cytogenetic analysis), 11–12
CD19
 bispecific antibodies, 188–189
 CAR T-cell therapy, 189–190
 dual CD19 and CD22 targeting CAR T-cell therapy, 191
CD22
 CAR T-cell therapy, 190–191
 CD22-targeted antibody-drug conjugate, 190
 dual CD19 and CD22 targeting CAR T-cell therapy, 191
Cell-based models
 blood cancers, 73–74
 brain tumors, 69–71
Cell cycle regulators, in osteosarcoma, 152
Cell fate determination, 92–97
Cell-free DNA (cfDNA), 44–45
Cell-intrinsic processes during development, errors in, 56–57
Cellular fitness assays, 172
Cellular metabolism, therapies targeting
 amino acid homeostasis, 240–242
 antimetabolites, 239–240
 asparaginase, 240–242
 cell signaling pathways, 242–243
 immunometabolism, 244–245
 introduction, 237–239
 isocitrate dehydrogenase (IDH) mutations, 243–244
 oxidative and reductive stress, 246–247
 review, 237–248
 success versus failure, 247–248

- Chemotherapy
 - acute lymphoblastic leukemia (ALL), 226–231
 - combination, 226, 228–231
 - history in treating childhood malignancies, 226–231
 - intrathecal, 228–229
 - lymphodepleting, 262–263
 - neoadjuvant, 226, 231
 - Chimeric antigen receptor T cells (CAR T cells). *See* CAR T-cell therapy
 - CHK1, 246
 - Chondrocytes, 150, 152
 - Chromatin, aberrant organization of, 276
 - Chromatin complexes, targeting, 275, 285–286
 - Chromatin remodeling, 56, 93, 95, 170, 179, 283
 - Chromosomal breakage disorders, 25
 - Chromosomal instability syndromes, 10
 - Chromosomal translocations, 84, 216, 275–276
 - Chromothripsis, 154
 - Circulating tumor DNA (ctDNA), 44–45, 200
 - CNS leukemia, 228
 - CNS tumors. *See also* Brain tumors
 - incidence in adults, 37
 - Li–Fraumeni syndrome (LFS), 38
 - Conflict theory, 60
 - Conventional cytogenetic analysis (CCA), 11–12
 - Copy number loss of heterozygosity (CN-LOH), 13
 - Core regulatory circuits (CRCs)
 - definition, 169
 - gene regulatory network (GRN) compared, 175–176
 - introduction, 170
 - model, 169–171, 173–176, 178–180
 - overview, 173–175
 - rhabdomyosarcoma, 92–93
 - structure and architectures, 174
 - CpG islands, 276
 - CSCs (cancer stem cells), 129, 135, 137–138, 140–141, 199
 - CSGs (cancer susceptibility genes), 37, 44
 - Cytokine release syndrome, 262
 - Cytokines, and treatment resistance, 198
- D**
- Decitabine, 156–157, 275–277, 295
 - Denys–Drash syndrome, 57
 - Dependency. *See also* Lineage-selective dependencies
 - common essential dependencies, 169, 171
 - definition, 169
 - relationship to lineage, 171–173
 - Developmental dysregulation
 - developmental model of pediatric oncogenesis, 55
 - epigenetic and microenvironmental factors, 59–61
 - features, 54
 - genetic factors, 56–59
 - historic clinicopathological observation, 54–56
 - introduction, 53–54
 - mutational signatures, 57
 - organogenesis relationship with tumorigenesis, 57
 - review, 53–62
 - Developmental modeling of childhood cancers
 - animal models, 68–69
 - blood cancers and MDS, 73–74
 - bone and soft tissue tumors, 74–75
 - brain tumors, 69–73
 - cell-based models of blood cancers, 73–74
 - genetically engineered mouse models (GEMMs), 69–73, 75
 - major types of models, 68–69
 - mouse models of brain tumors, 71–73
 - neuroblastoma, 75
 - overview, 67–68
 - patient-derived cells, 68
 - retinoblastoma, 75–76
 - review, 67–76
 - stem cell–based models, 68
 - Developmental mutagenesis, 2–4
 - Developmental mutators, 3–5
 - Developmental nuclease-enzyme hypothesis, 4
 - Developmental signaling, and tumor microenvironment (TME), 125–141
 - Dexrazoxane, 232
 - Diamond–Blackfan anemia, 11, 155
 - Diamond–Blackfan-associated genes, 17
 - Differentiation therapy, 213
 - Diffuse midline glioma (DMG), 69–72
 - Dinutuximab, 192, 198, 232
 - Disseminated tumor cells (DTCs), 126, 132
 - DNA hypermethylation, 275–277
 - DNA methylation, 44, 276–277, 281
 - DNA methyltransferases (DNMTs), 276–277
 - Donors, of hematopoietic stem cell transplant (HSCT), 25–26
 - Dosage selection
 - designing dose-finding trials, 307–309
 - dose-finding studies, 306–307
 - history of, 307–308
 - leveraging data from adults and pediatric populations, 306
 - model-informed drug development (MIDD), 308–309
 - starting dosage for dose-finding trials, 308
 - unique considerations in pediatrics, 308
 - Dose-limiting toxicities (DLTs), 307
 - DOTIL inhibitors, 283–284
 - Driver mutations
 - adult and childhood cancers compared, 56
 - B-cell acute lymphoblastic leukemia (B-ALL), 59
 - Drug development, pediatric cancer
 - advent, expectations, and challenges, 297–305
 - continuing challenges and requirement for innovation, 305–306
 - formulation, age-appropriate, 309–310
 - historical experience, 293–294
 - immunotherapy approach, 299, 304–305
 - legislative programs directed at facilitating, 294–296
 - molecular landscape for, 298–299
 - regulatory framework, 296–297
 - review, 293–310
 - tailoring to pediatric cancer, 299, 304–305
 - tumor strategic interactions, unraveling, 305

Index

DTCs (disseminated tumor cells), 126, 132
Dyskeratosis congenita, 25

E

Early diagnosis and risk stratification from birth, 36, 40–44
EAT (ex vivo arming of T cells), 198–199
EBV⁺ lymphomas, 17
ECM. *See* Extracellular matrix
Emapalumab, 232
Embryonal rhabdomyosarcoma (ERMS), 84–85, 88, 90
Embryonal solid tumor. *See also* Rhabdomyosarcoma
 locations of occurrence, 83–84
 tumorigenesis, 84
EMT (epithelial-to-mesenchymal transition), 126–127,
 129, 137, 139–140
Enasidenib, 277
EndoMT (endothelial-to-mesenchymal transition), 126,
 131
Endothelial cells during development, 130–131
Environmental agents, mutational signatures for, 57
Ependymoma, mouse models of, 72–73
Epigenetic code, 276
Epigenetic remodeling, 93
Epigenetics
 developmental dysregulation, 59–61
 developmental tumorigenesis, 5
 early diagnosis and risk stratification from birth, 44
 Li–Fraumeni syndrome (LFS), 44
 osteosarcoma pathogenesis, 157
 Waddington landscape, 95
Epigenetic therapies
 chromatin complexes, targeting, 275, 285–286
 DNA methylation, 276–277, 281
 FDA-approved, 278–280
 histone modifications, 275, 281–285
 introduction, 275–276
 review, 275–276
Epithelial-to-mesenchymal transition (EMT), 126–127,
 129, 137, 139–140
ERMS (embryonal rhabdomyosarcoma), 84–85, 88, 90
Erythrocyte adenosine deaminase, 11
Estrogen, and osteosarcoma development, 156
Evolutionary pressure, negative, 3
Evolutionary trade-offs, 3–4
Ewing sarcoma, 74–75
Extracellular matrix (ECM)
 during development, 131–132
 proteins secreted by osteoblasts, 150
 remodeling, 126, 128–132, 136–137, 140
Extracranial solid tumors, and Ras pathway alterations,
 111–112

F

Fanconi anemia (FA)
 genetic predisposition syndrome, 9–10, 25
 treatment, 25–26
Farber, Sidney, 226, 230, 239, 294

FGF/WNT signaling, in muscle development, 86
Fibroblasts
 cancer-associated fibroblasts (CAFs), 126, 129–131,
 135–136, 138–139, 158–159, 259
 in development, 129–130
Final Rule on Pediatric Labeling, 295
Fluorescent in situ hybridization (FISH), 11–12
Food and Drug Administration (FDA)
 approved therapies, 278–280
 pediatric cancer drug development, 293, 295–296,
 300–303
Food and Drug Administration Amendments Act
 (FDAAA), 295–296
Food and Drug Administration Modernization Act
 (FDAMA), 295
Food and Drug Administration Reauthorization Act
 (FDARA), 296–298, 305
Food and Drug Administration Safety and Innovation Act
 (FDASIA), 295–296
Formulation, age-appropriate, 309–310
Functional genomic screens, 170
Fusion proteins in rhabdomyosarcoma (FP-RMS), 74,
 84–86, 89, 91–96

G

GATA2 deficiency, 9–10
GCTs (germ cell tumors), 60–61
GD2, immunotherapies targeting
 bispecific antibodies (BsAbs), 193
 CAR T-cell therapy, 192–193, 199
 monoclonal antibodies, 192
 radioimmunotherapy, 193–195
 review, 191–195
 vaccines, 195–196
GEFs (guanine nucleotide exchange factors), 107, 117
Gene fusions, in rhabdomyosarcoma, 74, 84–86, 89,
 91–96
Generative adversarial networks (GANs), 46
Gene regulatory network (GRN)
 core regulatory circuit (CRC) compared, 175–176
 definition, 169
 introduction, 170
 overview, 175–178
 structure and architectures, 174
Genetically engineered mouse models (GEMMs), 69–73, 75,
 114
Genetic dependency, 171
Genetic dependency assays, 169
Genetic factors, in developmental dysregulation, 56–59
Genetic predisposition syndrome (GPS)
 bone marrow analysis, 11–12
 cascade testing and reproductive considerations, 27–28
 chromosome breakage, 10
 clinical history and symptoms/signs, 8–9
 diagnostic considerations, 8–16
 disease surveillance, 26–27
 erythrocyte adenosine deaminase, 11
 genes associated, 18–24

germline genetic testing modalities, interpretation, and limitations, 12–16
to hematologic malignancies, 7–28
nonmolecular tests in diagnostic workup, 9–12
overview, 7–8, 16–17
pancreatic trypsinogen and pancreatic isoamylase, 10–11
review, 7–28
telomere length, 10
treatment considerations, 17, 25–28
Genomic imprinting, 60–61
Germ cell tumors (GCTs), 60–61
Germline genetic testing
 modalities, interpretation, and limitations, 12–16
 panels, 14–15
Germline variants
 Diamond–Blackfan-associated genes, 17
 hematologic malignancy, 16
 Li–Fraumeni syndrome (LFS), 35, 37
 overview, 35
 somatic rescue, 12
 VAF (variant allele frequency), 13
Glioma
 diffuse midline glioma (DMG), 69–72
 high-grade gliomas (HCG), 113
 low-grade gliomas (LCG), 112
 oncohistone mutations, 59
GPS. *See* Genetic predisposition syndrome
GRN. *See* Gene regulatory network
GTPase switch, properties of Ras, 105–107
Guanine nucleotide exchange factors (GEFs), 107, 117

H

HATs (histone acetyltransferases), 281
HDAC (histone deacetylase), 281
Hedgehog (HH) signaling pathway, 134, 137–138
Hematologic malignancies. *See also specific cancers*
 genetic predisposition to, 7–28
 Ras pathway alterations, 110–111
Hematopoietic stem cell transplant (HSCT), 8, 25–26
High-grade gliomas, 113
Hippocrates, 1
Hippo pathway, 134, 136–137
Histiocytic disorders
 Langerhans cell histiocytosis (LCH), 111
 Ras pathway alterations, 111
Histone acetylation, 281–282
Histone acetyltransferase inhibitors, 281–282
Histone acetyltransferases (HATs), 281
Histone deacetylase (HDAC), 281
Histone deacetylase (HDAC) inhibitors, 281
Histone deacetylation, 281
Histone demethylation, 282–285
Histone genes, mutations in, 69–72
Histone methylation, 282–285
Histone methyltransferase, 283–284
Histones
 epigenetic therapies, 275, 281–285

 mutations, 58–59
 posttranslational modifications (PTMs), 58, 281–285
History
 development of contemporary treatment of childhood malignancies, 225–233
 pediatric cancer drug development, 293–294
Hot versus cold tumors, 257, 299, 304–305
HRAS mutations, 105, 110, 112–113, 117
Humanized mice, 73
Hypermethylation, DNA, 275–277
Hypermutation, 37

I

ICIs (immune checkpoint inhibitors), 187, 198, 200, 244, 299, 304
IDH (isocitrate dehydrogenase)
 inhibitors, 275, 277, 281
 mutations, 243–244, 277, 281
IFN signaling, PML role in, 217
IGF-I (insulin-like growth factor I), 156
IGF2, 60
Imatinab, 231
Immune checkpoint blockade, 160
Immune checkpoint inhibitors (ICIs), 187, 198, 200, 244, 299, 304
Immunometabolism, 244–245
Immunotherapies
 B-cell lymphocyte antigens, targeting, 188–191
 CD19 bispecific antibodies, 188–189
 CD19-CAR T-cell therapy, 189–190
 CD22-CAR T-cell therapy, 190–191
 CD22-targeted antibody-drug conjugate, 190
 combination, 199–200
 CSCs (cancer stem cells), targeting, 129, 199
 current and future directions, 231
 drug development, 299, 304–305
 dual CD19 and CD22 targeting CAR T-cell therapy, 191
 GD2 bispecific antibodies (BsAbs), 193
 GD2 CAR T-cell therapy, 192–193
 GD2 monoclonal antibodies, 192
 GD2 targeting radioimmunotherapy, 193–195
 introduction, 187–188
 multiantigen targeting (cocktailing) approaches, 199
 pediatric cancer vaccines, 195–196
 review, 187–201
 strategies to overcome treatment resistance, 196–200
Imprinting, 5, 60–61
Incidence, age-dependent, 3
Indian Hedgehog (IHH), 137–138, 150–151
Induced pluripotent stem cells (iPSCs), 89
Initial Pediatric Study Plan (iPSP), 295–296
Innate immunity, and osteosarcoma (OS), 159–160
Insulin-like growth factor I (IGF-I), 156
Intensity-modulated radiotherapy (IMRT), 232
Interleukin 2 (IL-2), 137–138, 195, 260–261
Interleukin 6 (IL-6), 158, 161
Interleukin 8 (IL-8), 134, 259
Interleukin 10 (IL-10), 128, 259

Index

- Interleukin 15 (IL-15), 191, 198
Intrathecal therapy, 228–229
Invariant NK T (iNKT)-cell products, 262
ISL1, 172, 175, 178
Isocitrate dehydrogenase. *See* IDH (isocitrate dehydrogenase)
Ivosidenib, 277, 281
- J**
- Juvenile myelomonocytic leukemia (JMML), 111
- K**
- KEAP1, 246
Keyhole limpet hemocyanin (KLH), 195–196
KMT2A fusions, 283–284, 285–286
KMT2A (lysine methyltransferase 2A) gene, 283–284
K-Ras inhibitors, 116
KRAS mutations, 57, 105, 109–111, 113–116
- L**
- Labeling information, 294
Langerhans cell histiocytosis (LCH), 111
Legislative programs directed at facilitating pediatric drug development, 294–296
Leukemia. *See also specific cancers*
 CNS, 228
 incidence in adults, 37
Li–Fraumeni syndrome (LFS)
 cancer-preventative interventions, 40
 cancer risk reduction, 46–47
 cancer surveillance, 38–46
 clinical criteria for diagnosis, 37–38
 clinical management, 35–48
 early diagnosis and risk stratification from birth, 36, 40–44
 epigenetics, 44
 introduction, 37–38
 noninvasive cancer screening and monitoring, 44–45
 pharmacological cancer risk reduction, 46–47
 TP53 alterations, 154
Lineage, relationship with dependency, 171–173
Lineage-selective dependencies
 definition, 169
 as enriched in factors regulating gene expression, 168
 introduction, 167–171
 neuroblastoma as model of, 172–173
 relationship between lineage and dependency, 171–173, 175–180
 review, 167–180
Low-grade gliomas, 112
Lung metastasis, in osteosarcoma, 161
Lymphodepleting chemotherapy, 262–263
Lymphomas, 37
- M**
- Machine learning for cancer surveillance, 45–46
Macrophages
 in development, 128–129
 tumor-associated macrophages (TAMs), 127–131, 135, 137–138, 140, 160, 196–198, 259–260
Magnetic resonance imaging (MRI), whole-body, 45–46
Malformation, link to mutation, 59
Malignant ectomesenchymoma, 112
Malignant peripheral nerve sheath tumor (MPNST), 75, 112
Malignant rhabdoid tumor, 60
MAP (methotrexate, adriamycin, and cisplatin), 231
MAPK. *See* Ras/MAPK pathway
Maturation block, 56, 59, 61–62
Maximum tolerated dose (MTD), 307–308
MDS. *See* Myelodysplastic syndrome
MDSCs (myeloid-derived suppressor cells), 128–131, 135, 137, 196, 259
Medulloblastoma, 72
MEK inhibitors, allosteric, 114–115
Men1, 285–286
Menin inhibitors, 285–286
Mesenchymal-to-epithelial transition (MET), 126–127
Metabolic dysregulation, targeting, 46
Metabolism. *See* Cellular metabolism, therapies targeting
Metastasis, in osteosarcoma, 157, 159, 161
Metformin, 46–47
Methotrexate, 226–229, 231, 240, 293
Methylation
 DNA, 276–277, 281
 genomic imprinting, 60–61
 histone, 282–285
MHC loss/down-regulation, 257
Microenvironmental factors, in developmental dysregulation, 59–61
Minimal residual disease (MRD), 188–190, 229
Mismatch repair, 54, 57, 299
Model-informed drug development (MIDD), 308–309
Models. *See also* Developmental modeling of childhood cancers
 acute promyelocytic leukemia (APL), 212–217
 integrative of cancer development, 4–5
 for preclinical testing, 113–114
 rhabdomyosarcoma (RMS), 74, 88–92
Molecular profiling methods, 41, 43
Monoclonal antibodies, 188, 192, 232, 298
Monosomy 7, 11–13
Mouse models
 acute promyelocytic leukemia (APL), 212–217
 brain tumors, 71–73
 genetically engineered mouse models (GEMMs), 69–73, 75, 114
 osteosarcoma, 152
MPNs (myeloproliferative neoplasms), 110–111, 217
MPNST (malignant peripheral nerve sheath tumor), 75, 112
MRD (minimal residual disease), 188–190, 229
MRFs (myogenic regulatory factors), 87, 89
MRI, whole-body, 45–46
mRNA vaccines, 195
MTD (maximum tolerated dose), 307–308
mTOR signaling, 57, 91, 156, 242–243
Multistage mutation model, 1–2

- Muscle development, 85–88
Mutational burden, 2, 114, 160, 167, 188, 200, 257, 298–299
Mutational signatures, 3–4, 57
Myc, in osteosarcoma, 152
MYCN amplification, 58
Myelodysplastic syndrome (MDS)
 bone marrow analysis, 11–12
 germline testing, 8
 modeling, 74
Myeloid cells, in osteosarcoma, 159–160
Myeloid-derived suppressor cells (MDSCs), 128–131, 135, 137, 196, 259
Myeloproliferative neoplasms (MPNs), 110–111, 217
MYF5, 87–88
MYOG, 87, 91, 96
Myogenesis. *See* Muscle development
Myogenic regulatory factors (MRFs), 87, 89
- N**
- Naxitamab, 192
NDA (New Drug Application), 295–296
Neural crest cells (NCCs), 173, 177–179
Neural crest development, 171–173
Neural crest gene regulatory network, 176–180
Neuroblastoma (NB)
 ASCL1 in, 178–179
 bispecific antibodies (BsAbs), 196
 CAR T-cell therapy, 196
 core regulatory circuit (CRC), 175, 176
 developmental dysregulation, 55–56
 gene regulatory network (GRN), 175, 177–180
 immunotherapies, 187–188, 191–196, 198–199
 lineage-selective dependencies, 171–173
 modeling, 75
 SOX11 in, 179–180
 vaccines, 195–196
Neurofibromatosis type 1 (NF1) disorder, 109–110
Neurotropic tyrosine receptor kinase (NTRK), 56
New Drug Application (NDA), 295–296
Next-generation sequencing, 12
NFI, 105–107, 109–116, 118, 198
Nijmegen breakage, 25
Noonan syndrome, 109–110
Notch signaling
 overview, 134–136
 in rhabdomyosarcoma (RMS), 94
 signal-mediated toggle switch, 177–179
NPM1, 217
NRAS mutations, 105, 109–117
NRF2, 246
NTRK (neurotropic tyrosine receptor kinase), 56
Nucleoside analogs, 239–240
Nucleotide synthesis, inhibitors of, 238–240
- O**
- Olutasidenib, 281
Oncogenic fusion proteins, 275–276, 283–286
Oncohistone mutations, 58–59, 69
Organogenesis, relationship with tumorigenesis, 57
Organoid-based models, 70–71
Osteoblasts, 139, 150–152, 154–159
Osteoclasts, 139, 150–152, 159
Osteocytes, 150–152
Osteosarcoma (OS)
 cell of origin, 150–152
 genomics at intersection of puberty and growth, 155–156
 genomics through developmental lens, 152–157
 germline predisposition syndromes, 154–155
 innate immunity, 159–160
 introduction, 149–150
 Li–Fraumeni syndrome (LFS) and, 38, 41
 lung metastatic niche, 161
 microenvironment, 157–161
 mouse models, 152
 osteoclast roles in pathogenesis, 159
 primary bone and metastatic niche, 158
 review, 149–162
 signaling pathways in osteoblastic lineage, 150–151
 somatic copy-number alterations in, 152–153, 156
 stromal cell and vascular contributions, 157–159
 T-cell activation and targeting the OS surfaceome, 160–161
 therapeutic opportunities, 156–157
 treatment, 230–231
Oxidative stress, 246–247
- P**
- Paget disease of bone, 155
Pancancer analyses, 298
Pancreatic isoamylase, 10–11
Pancreatic trypsinogen, 10–11
Pan-Raf inhibitors, 115–116
Papillary craniopharyngioma, 112
Paralog synthetic lethal genetic relationships, 170
Parathyroid hormone-related protein (PTHrP), 150
Patient-derived cell lines, 68
Patient-derived xenografts (PDXs)
 malignant peripheral nerve sheath tumors, 75
 models for preclinical testing, 114, 118
 osteosarcoma models, 157
 for preclinical testing, 114
 rhabdomyosarcoma (RMS) models, 88, 97
 T-cell acute leukemia, 284
PAX3, in muscle development, 87, 92
PAX7, 84, 87, 89, 91, 93
PAX3-FOXP1 fusion, 74, 84, 89, 91
PD-L1 (programmed death-ligand 1), 260
Pediatric cancer vaccines, 195–196
Pediatric investigation plans (PIPs), 296
Pediatric Research Equity Act (PREA), 295–296
Pediatric Rule, 295
Pembrolizumab, 200
Peripheral nerve sheath tumors, 75

Index

- Personalized cancer surveillance, 40–46
PGBD5, 4
Philadelphia chromosome mutations, 229
PI3K/AKT/mTOR signaling, 91, 156, 242–243
PI3K pathway inhibitors, 242–243
PIPs (pediatric investigation plans), 296
Plane of transformation, 95–97
Pluripotent stem cells (PSCs), 68–71, 74–76
PML nuclear bodies (NBs), 211–212, 214–217
Positive feedback circuits, 174–177
Posttranslational modifications (PTMs)
 histones, 58, 281–285
 Ras, 108–109, 117
PREA (Pediatric Research Equity Act), 295–296
Precision medicine, 67, 76, 225, 231
Precision oncology, 41, 200, 243, 297–299, 305
Preclinical testing, models for, 113–114
Preimplantation genetic testing, 28
Premature somatic mosaicism, 3–5
Premetastatic niche (PreMN), 126–127, 132
Pretargeted radioimmunotherapy (PRIT), 194
Programmed death-ligand 1 (PD-L1), 260
Promyelocytic leukemia (PML)/retinoic acid receptor α (RARA) fusion oncoprotein, 209–217, 275, 285–286
Proteolysis targeting chimeras (PROTACs), 92, 214
PSCs (pluripotent stem cells), 68–71, 74–76
P53 signaling, PML role in, 212, 215–217
PTEN
 acute lymphoblastic leukemia (ALL), 107, 111
 osteosarcoma, 152
 rhabdomyosarcoma (RMS), 90–91
PTHrP (parathyroid hormone-related protein), 150
PTMs. *See* Posttranslational modifications
PTPN11, 110–111, 115–117
Puberty, and osteosarcoma development, 156
- R**
- RACE (Research to Accelerate Cures and Equity), 296
Radiation therapy, history of use, 225–226, 228–230, 232
Radioimmunotherapy (RIT), 193–195
Raf kinase inhibitors, first-generation, 115
RAG1/2, 3–4
Rapamycin, 47
RARA (retinoic acid receptor α), 175, 209–216, 275, 285–286
Ras
 GTPase switch, properties of, 105–107
 hypervariable region of Ras protein, 108
 intracellular trafficking, 108–109
 isoforms, 108–109
 oncogenic proteins and therapeutic implications, 109
 posttranscriptional modification inhibitors, 117
 posttranscriptional modifications, 108–109
Ras/MAPK pathway, 107, 109–111, 113, 115–118, 156
RAS mutations in human cancer, 105–109
RASopathies, 109–110
Ras pathway alterations
 acute lymphoblastic leukemia (ALL), 111
 acute myeloid leukemia (AML), 110–111
 brain tumors, 112–113
 extracranial solid tumors, 111–112
 hematologic malignancies, 110–111
 high-grade gliomas (HGGs), 113
 histiocytic disorders, 111
 juvenile myelomonocytic leukemia (JMML), 111
 Langerhans cell histiocytosis (LCH), 111
 low-grade gliomas (LGGs), 112
 malignant peripheral nerve sheath tumor (MPNST), 112
 papillary craniopharyngioma, 112
 rhabdomyosarcoma (RMS), 85, 111–112
Ras signaling
 models for preclinical testing, 113–114
 therapies targeting, 114–117
Ras signaling, therapies targeting
 allosteric MEK inhibitors, 114–115
 K-Ras inhibitors, 116
 pan-Raf inhibitors, 115–116
 Raf kinase inhibitors, first-generation, 115
 Ras posttranslational modification inhibitors, 117
 review, 114–117
 SHP2 inhibitors, 116–117
 switch II pocket inhibitors, 116
RCAS system, 71–72
Reactive nitrogen species (RNS), 246
Reactive oxygen species (ROS), 246
Recommended phase 2 dose (RP2D), 307–308
Reductive stress, 246–247
Regulatory framework for pediatric cancer drug development, 296–297
R-enantiomer of 2-hydroxyglutarate (R-2HG), 243–244
Reproductive considerations, 27–28
Resistance, strategies to overcome treatment, 196–200
Retinoblastoma, 75–76, 155
Retinoic acid, 86, 157, 209–210, 213–217, 285–286
Retinoic acid receptor α (RARA), 175, 209–216, 275, 285–286
Retinoic acid receptor β (RAR β), 210, 212
Retinoic acid receptor γ (RAR γ), 210, 212
Rhabdomyosarcoma (RMS)
 cell fate control, 92–95
 developmental heterogeneity of, 83–97
 models, 74, 88–92
 overview, 84–85
 Ras pathway alterations, 85, 111–112
 subtypes, 84–85
Risk stratification from birth, 36, 40–44
Risk-stratified therapy, 225–226, 229–230, 232
RIT (radioimmunotherapy), 193–195
Rituximab, 232
RMS. *See* Rhabdomyosarcoma
Rothmund–Thomson syndrome, 155
RP2D (recommended phase 2 dose), 307–308
RUNX1, 11–13, 25–26, 74, 178–179, 229, 244
RUNX2, 150–152, 178–179

- S**
- SCNA (somatic copy-number alteration), 152–153, 156
 - Screening
 - functional genomic screens, 170
 - noninvasive, 44–45
 - Second site mutation, 13
 - Severe congenital neutropenia (SCN), 11–12
 - SGR (somatic genetic rescue), 13
 - SHH. *See* Sonic hedgehog (SHH) signaling
 - SHP2 inhibitors, 116–117
 - Shwachman–Diamond syndrome (SDS), 10–13, 26–27
 - Signaling pathways. *See also specific pathways*
 - in osteoblastic lineage, 150–151
 - treatments targeting, 242–243
 - tumor microenvironment (TME), 132–141
 - Signal-mediated toggle switch, 174–175, 177–179
 - Sinusoidal obstruction syndrome (SOS), 190
 - SMARCB1*, 4, 60, 70, 72, 304
 - Social determinants of health, 232–233
 - Soft tissue sarcomas (STSs), 38, 41
 - Soft tissue tumors, 74–75
 - Solid tumors
 - adoptive cell therapy (ACT) for, 255–266
 - embryonal, 83–84
 - extracranial, 111–112
 - Somatic copy-number alteration (SCNA), 152–153, 156
 - Somatic genetic rescue (SGR), 13
 - Somatic mosaicism, 1–5
 - Somitogenesis, 86–87
 - Sonic hedgehog (SHH) signaling
 - brain tumors, 41, 70, 72
 - overview, 137–138
 - rhabdomyosarcoma (RMS), 90, 94, 96
 - SOS (sinusoidal obstruction syndrome), 190
 - SOX9*, 178–179
 - SOX10*, 177
 - SOX11*, 179–180
 - Sox/Oct pathway, 134, 140–141
 - Spindle cell/sclerosing RMS, 84–85
 - Stem cell–based models, 68
 - STSs (soft tissue sarcomas), 38, 41
 - Sumoylation, 212, 215, 217
 - Surgery, history of use, 225–226, 230–231
 - Surveillance, epidemiology, and end results (SEER) program, 3
 - SUZ12*, 112
 - Switch II pocket inhibitors, 116
 - Switch/sucrose nonfermentable (SWI/SNF), 93, 95–96, 179, 283, 304
 - Synthetic lethality, 170
- T**
- TAA (tumor-associated antigens), 256–257, 260, 262
 - TAA-T (tumor-associated antigen)-specific T cells, 257
 - TAMs (tumor-associated macrophages), 127–131, 135, 137–138, 140, 160, 196–198, 259–260
 - TAZ, 136–137
 - Tazemetostat, 283
 - TBDs (telomere biology disorders), 9–10, 25–26
 - T-cell acute lymphoblastic leukemia (T-ALL)
 - history of treatment approaches, 229
 - Ras pathway alterations, 111
 - T cells
 - response inhibition by arginine depletion, 245
 - T regulatory (Treg) cells, 129, 196, 198
 - TCR-specific ACT products, 262
 - Telomere biology disorders (TBDs), 9–10, 25–26
 - Telomere length testing, 10
 - Tet methylcytosine dioxygenase 2 (*TET2*), 277
 - TGF- β (transforming growth factor β) signaling, 134, 138–139
 - TIAA (tumor-associated antigen)-specific T cells (TAA-T), 257
 - TILs (tumor-infiltrating lymphocytes/leucocytes), 161, 256, 260–261
 - TIMs (tumor-infiltrating myeloid cells), 198
 - Tisagenlecleucel, 188–189
 - TKIs (tyrosine kinase inhibitors), 157, 229, 231
 - TMB (tumor mutational burden), 298–299, 304
 - TME. *See* Tumor microenvironment
 - TMME (tumor metabolic microenvironment), 139
 - Toggle switch, signal-mediated, 174–175, 177–179
 - Toxicity, dose-limiting (DLT), 307
 - TP53*
 - aging-associated cancers in adults, 2
 - developmental modeling of brain tumors, 70–71
 - genetic predisposition syndrome, 12, 17, 26
 - Li–Fraumeni syndrome (LFS), 35, 37–42, 44–48, 154
 - osteosarcoma (OS), 154
 - rhabdomyosarcoma (RMS), 89–92
 - TRAFACs. *See* Transcription factor targeting chimeras
 - Transcription factors. *See also specific factors*
 - ASCL1*, 178–179
 - in bone development, 151
 - cell fate determination, 92–97
 - core regulatory circuit (CRC) model, 170, 173–175
 - gene regulatory network (GRN), 175–180
 - lineage-selective dependencies, 169–172, 174–175, 177–180
 - in muscle development, 87–88
 - SOX11*, 179–180
 - Transcription factor targeting chimeras (TRAFACs), 180
 - Transforming growth factor β (TGF- β) signaling, 134, 138–139
 - Treatment. *See also specific malignancies; specific modalities*
 - acute lymphoblastic leukemia (ALL), 226–233
 - acute promyelocytic leukemia (APL), 209–210, 212–216
 - adoptive cell therapy (ACT) for solid tumors, 255–266
 - cellular metabolism, targeting, 237–248
 - contemporary, 225–233
 - current and future directions, 231
 - disease surveillance in genetic predisposition syndrome (GPS), 26–27
 - epigenetic therapies, 275–286
 - FDA-approved therapies, 278–280

Index

Treatment (*Continued*)

- hematologic diagnosis with underlying genetic predisposition syndrome (GPS), 17, 25–28
 - immunotherapies, 187–201
 - Li–Fraumeni syndrome (LFS), clinical management of, 35–48
 - lineage-selective dependencies as target, 167
 - metabolic dysregulation, targeting, 46
 - monoclonal antibodies, 188, 192, 232, 298
 - osteosarcoma (OS), 156–157, 230–231
 - pediatric cancer drug development, 293–310
 - radiation therapy, 225–226, 228–230, 232
 - Ras signaling, targeting, 109, 114–117
 - risk-stratified therapy, 225–226, 229–230, 232
 - surgery, 225–226, 230–231
 - Wilms tumor, 230
- T regulatory (Treg) cells, 129, 196, 198
- TRUCKs, 262
- Tumor-associated antigens (TAAs), 256–257, 260, 262
- Tumor-associated macrophages (TAMs), 127–131, 135, 137–138, 140, 160, 196–198, 259–260
- Tumorigenesis, relationship with organogenesis, 57
- Tumor-infiltrating lymphocytes/leucocytes (TILs), 161, 256, 260–261
- Tumor metabolic microenvironment (TMME), 139
- Tumor microenvironment (TME)
- cell types and cell–cell interactions, 126–131
 - developmental pathways, 132–141
 - developmental signaling, 125–141
 - endothelial cells during development, 130–131
 - extracellular matrix (ECM) during development, 131–132
 - features, 126–131
 - fibroblasts in development, 129–130
 - immune evasion tactics of, 258–259
 - immunometabolism in, 245
 - immunosuppressive, 257–260
 - introduction, 125–126
 - macrophages in development, 128–129
 - modifiers in combination GD2, immunotherapies, 196–200
 - noncellular components, 131–141
 - osteosarcoma, 157–161
 - phenotypic states of cells, 126
 - premetastatic niche (PreMN), 132
- Tumor microenvironment (TME) developmental signaling pathways
- bone morphogenetic protein (BMP), 134, 139–140
 - Hedgehog (HH), 134, 137–138
 - Hippo, 134, 136–137
 - introduction, 132

- Notch, 134–136
 - protumorigenic roles in TME, 133
 - review, 132–141
 - Sox/Oct, 134, 140–141
 - transforming growth factor β (TGF- β), 134, 138–139
 - Wnt, 132–135
- Tumor mutational burden (TMB), 298–299, 304
- Tyrosine kinase inhibitors (TKIs), 157, 229, 231

U

- Uniparental disomy, 12–13

V

- Vaccines, pediatric cancer, 195–196
- Variant allele frequency (VAF), 12–13
- Variants of uncertain significance (VUSs), 16, 25, 37
- Vascular endothelial growth factor (VEGF) inhibitors, 198
- Vincristine, 230
- Virus-specific T cells (VSTs), 262
- Vorasidenib, 281

W

- Waddington's epigenetic landscape, 95
- WAGR syndrome, 57
- Warburg, Otto, 237, 239
- Werner syndrome, 155
- Wilms tumor
- developmental dysregulation, 54, 56, 58, 60–61
 - treatment, 230
- Wnt signaling, 132–135
- World Health Organization (WHO) leukemia classification system, 8
- WT1* gene, 57–58, 256

X

- Xenografts
- malignant peripheral nerve sheath tumors, 75
 - osteosarcoma models, 156–157
 - for preclinical testing, 113–114, 118
 - rhabdomyosarcoma (RMS) models, 88, 97
 - T-cell acute leukemia, 284

Y

- YAP, 136–137